Homeopathy 2013; 102(03): 215-224
DOI: 10.1016/j.homp.2013.05.001
Copyright © The Faculty of Homeopathy 2013

Immunomodulatory drugs (natalizumab), worsening of multiple sclerosis, rebound effect and similitude

Marcus Zulian Teixeira

Subject Editor:
Further Information

Publication History

Received12 June 2012
revised15 January 2013

accepted02 May 2013

Publication Date:
29 December 2017 (online)

Background Homeopathic treatment is based on the principle of similitude (‘like cures like’) administering to sick individuals substances that cause similar symptoms in healthy individuals, employing the paradoxical or biphasic action of the organism as therapeutic response. This homeostatic, vital or secondary action of the organism is scientifically explained by the rebound effect of drugs, resulting in worsening of symptoms after enantiopathic treatment withdrawal. Natalizumab reduces relapses in patients with active multiple sclerosis (MS), but recent studies report severe worsening of MS after suspension of treatment, as a consequence of the rebound effect.

Method Extending this source of evidence, this work reviews research that demonstrates secondary worsening of MS after discontinuation of natalizumab, a human monoclonal antibody that suppresses the disease inflammatory activity as primary action.

Results Several studies refer to the immune reconstitution inflammatory syndrome (IRIS) as a plausible explanation of reactivation of MS after withdrawal of natalizumab: a rebound effect or secondary action of the organism in response to the primary immunosuppression caused by the drug.

Conclusion Relapses of MS after discontinuation of natalizumab treatment indicate rebound of disease activity, supporting the homeopathic principle and warning healthcare professionals about this serious iatrogenic event.

  • References

  • 1 Hahnemann S. Essay on a new principle for ascertaining the curative power of drugs, with a few glances at those hitherto employed. In: Dudgeon R.E. (ed). The lesser writings of Samuel Hahnemann. 1995. New Delhi: B. Jain Publishers; (Reprint edition).
  • 2 Hahnemann S. Organon of medicine. (Translated by William Boericke) 6th edn. New Delhi: B Jain Publishers; 1991.
  • 3 Teixeira M.Z. Semelhante cura semelhante: o princípio de cura homeopático fundamentado pela racionalidade médica e científica. Similar cures similar: the homeopathic cure principle based by the medical and scientific rationality. São Paulo: Editorial Petrus; 1998.
  • 4 Teixeira M.Z. Similitude in modern pharmacology. Homeopathy 1999; 88 (03) 112-120.
  • 5 Teixeira M.Z. Evidence of the principle of similitude in modern fatal iatrogenic events. Homeopathy 2006; 95 (04) 229-236.
  • 6 Teixeira M.Z. NSAIDs, myocardial infarction, rebound effect and similitude. Homeopathy 2007; 96 (01) 67-68.
  • 7 Teixeira M.Z. Bronchodilators, fatal asthma, rebound effect and similitude. Homeopathy 2007; 96 (02) 135-137.
  • 8 Teixeira M.Z. Antidepressants, suicidality and rebound effect: evidence of similitude?. Homeopathy 2009; 98 (01) 114-121.
  • 9 Teixeira M.Z. Statins withdrawal, vascular complications, rebound effect and similitude. Homeopathy 2010; 99 (04) 255-262.
  • 10 Teixeira M.Z. Rebound acid hypersecretion after withdrawal of gastric acid suppressing drugs: new evidence of similitude. Homeopathy 2011; 100 (03) 148-156.
  • 11 Teixeira M.Z. Antiresorptive drugs (bisphosphonates), atypical fractures and rebound effect: new evidence of similitude. Homeopathy 2012; 101 (03) 231-242.
  • 12 Teixeira M.Z. Homeopathic use of modern medicines: utilisation of the curative rebound effect. Med Hypotheses 2003; 60 (02) 276-283.
  • 13 Teixeira M.Z. New homeopathic medicines: use of modern drugs according to the principle of similitude. Homeopathy 2011; 100 (04) 244-252.
  • 14 Pugliatti M., Rosati G., Carton H. et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006; 13 (07) 700-722.
  • 15 Horga A., Tintoré M. Natalizumab for relapsing-remitting multiple sclerosis. Neurologia 2011; 26 (06) 357-368.
  • 16 Runia T.F., van Pelt-Gravesteijn E.D., Hintzen R.Q. Recent gains in clinical multiple sclerosis research review. CNS Neurol Disord Drug Targets 2012; 11 (05) 497-505.
  • 17 Von Andrian U.H., Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003; 348 (01) 68-72.
  • 18 Kleinschmidt-DeMasters B.K., Miravalle A., Schowinsky J., Corboy J., Vollmer T. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol 2012; 71 (07) 604-617.
  • 19 Rice G.P., Hartung H.P., Calabresi P.A. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005; 64 (08) 1336-1342.
  • 20 Bomprezzi R., Okuda D.T., Alderazi Y.J., Stüve O., Frohman E.M. From injection therapies to natalizumab: views on the treatment of multiple sclerosis. Ther Adv Neurol Disord 2012; 5 (02) 97-104.
  • 21 Khatri B.O., Man S., Giovannoni G. et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009; 72 (05) 402-409.
  • 22 Tan I.L., McArthur J.C., Clifford D.B., Major E.O., Nath A. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 2011; 77 (11) 1061-1067.
  • 23 Polman C.H., O'Connor P.W., Havrdova E. et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354 (09) 899-910.
  • 24 Rudick R.A., Stuart W.H., Calabresi P.A. et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354 (09) 911-923.
  • 25 Miller D.H., Soon D., Fernando K.T. et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007; 68 (17) 1390-1401.
  • 26 Havrdova E., Galetta S., Hutchinson M. et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009; 8 (03) 254-260.
  • 27 Koralnik I.J. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name?. Ann Neurol 2006; 60 (02) 162-173.
  • 28 Weber T. Progressive multifocal leukoencephalopathy. Neurol Clin 2008; 26 (03) 833-854 x–xi.
  • 29 Carson K.R., Focosi D., Major E.O. et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009; 10 (08) 816-824.
  • 30 Bartt R.E. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy. Curr Opin Neurol 2006; 19 (04) 341-349.
  • 31 Yousry T.A., Major E.O., Ryschkewitsch C. et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354 (09) 924-933.
  • 32 Ryschkewitsch C.F., Jensen P.N., Monaco M.C., Major E.O. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol 2010; 68 (03) 384-391.
  • 33 Chen Y., Bord E., Tompkins T. et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009; 361 (11) 1067-1074.
  • 34 Gorelik L., Goelz S., Sandrock A.W. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009; 361 (25) 2487-2488.
  • 35 De Gascun C.F., Lonergan R.M., Hall W.W. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009; 361 (25) 2488-2489.
  • 36 Jilek S., Jaquiéry E., Hirsch H.H. et al. Immune responses to JC vírus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol 2010; 9 (03) 264-272.
  • 37 Tan C.S., Chen Y., Viscidi R.P. et al. Discrepant findings in immune responses to JC virus in patients receiving natalizumab. Lancet Neurol 2010; 9 (06) 565-566.
  • 38 Rudick R.A., O'Connor P.W., Polman C.H. et al. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 2010; 68 (03) 304-310.
  • 39 Killestein J., Vennegoor A., Strijbis E.M. et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol 2010; 68 (03) 392-395.
  • 40 Adelman B., Sandrock A., Panzara M.A. Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med 2005; 353 (04) 432-433.
  • 41 Langer-Gould A., Atlas S.W., Green A.J., Bollen A.W., Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353 (04) 375-381.
  • 42 Kleinschmidt-DeMasters B.K., Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353 (04) 369-374.
  • 43 Van Assche G., Van Ranst M., Sciot R. et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353 (04) 362-368.
  • 44 FDA. Tysabri (natalizumab): update of healthcare professional information. MedWatch: US Department of Health and Human Services; 2011 April 22. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm199965.htm.
  • 45 Sangalli F., Moiola L., Bucello S. et al. Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci 2011; 31 (Suppl. 03) 299-302.
  • 46 Kappos L., Bates D., Edan G. et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011; 10 (08) 745-758.
  • 47 FDA. Drug safety communication: new risk factor for Progressive Multifocal Leukoencephalopathy (PML) associated with Tysabri (natalizumab). 2012 Jan 20. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm288186.htm.
  • 48 Warnke C., Menge T., Hartung H.P. et al. Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?. Arch Neurol 2010; 67 (08) 923-930.
  • 49 Sandrock A., Hotermans C., Richman S. et al. Risk stratification for progressive multifocal leukoencephalopathy (PML) in MS patients: role of prior immunosuppressant use, natalizumab-treatment duration, and anti-JCV antibody status. Presented at the 63rd Annual Meeting of the American Academy of Neurology (AAN), April 9-16 2011 Honolulu, Hawaii, Abstract P03.248.
  • 50 Clifford D.B., De Luca A., Simpson D.M., Arendt G., Giovannoni G., Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9 (04) 438-446.
  • 51 Miravalle A., Jensen R., Kinkel R.P. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011; 68 (02) 186-191.
  • 52 Metz I., Radue E.W., Oterino A. et al. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol 2012; 123 (02) 235-245.
  • 53 Lenhard T., Biller A., Mueller W., Metz I., Schönberger J., Wildemann B. Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?. Neurology 2010; 75 (09) 831-833.
  • 54 Ramos-Cejudo J., Oreja-Guevara C., Stark Aroeira L. et al. Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism. J Clin Immunol 2011; 31 (04) 623-631.
  • 55 Benkert T.F., Dietz L., Hartmann E.M. et al. Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis. PLoS One 2012; 7 (12) e52208.
  • 56 O'Connor P.W., Goodman A., Kappos L. et al. Results of clinical and magnetic resonance imaging analyses following cessation of natalizumab dosing in patients with multiple sclerosis. Presented at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis. September 29, 2006. Madrid.
  • 57 O'Connor P., Goodman A., Kappos L. et al. Return of disease activity after cessation of natalizumab therapy in patients with multiple sclerosis (P793). Presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. September 9th, 2009. Düsseldorf. 2010.
  • 58 O'Connor P.W., Goodman A., Kappos L. et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 76 (22) 1858-1865.
  • 59 Vellinga M.M., Castelijns J.A., Barkhof F. et al. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 2008; 70 (13 Pt 2): 1150-1151.
  • 60 Rammohan K.W., Ortega M.R., Delgado S.R., Tornes L. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 77 (21) 1930; discussion 1930–1931.
  • 61 Tubridy N., Behan P.O., Capildeo R. et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999; 53 (03) 466-472.
  • 62 Fox R.J., Kappos L. Is natalizumab overshooting its rebound?. Neurology 2008; 70 (13 Pt 2): 1073-1074.
  • 63 Schiess N., Calabresi P.A. Natalizumab: bound to rebound?. Neurology 2009; 72 (05) 392-393.
  • 64 Perumal J., Hreha S., Bao F. et al. Post-natalizumab associated rebound or CNS immune reconstitution syndrome: clinical and MRI findings. Mult Scler 2009; 15 (Suppl. 02) S119.
  • 65 West T.W., Cree B.A. Natalizumab dosage suspension: are we helping or hurting?. Ann Neurol 2010; 68 (03) 395-399.
  • 66 Kerbrat A., Le Page E., Leray E. et al. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci 2011; 308 (1–2): 98-102.
  • 67 Borriello G., Prosperini L., Mancinelli C. et al. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. Eur J Neurol 2012; 19 (05) 783-787.
  • 68 Baumgartner A., Stich O., Rauer S. Clinical and radiological disease reactivation after cessation of long-term therapy with natalizumab. Int J Neurosci 2012; 122 (01) 35-39.
  • 69 Havla J.B., Pellkofer H.L., Meinl I., Gerdes L.A., Hohlfeld R., Kümpfel T. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch Neurol 2012; 69 (02) 262-264.
  • 70 Laroni A., Bedognetti M., Uccelli A., Capello E., Mancardi G.L. Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. Neurol Sci 2011; 32 (01) 181-182.
  • 71 Novartis. Media releases: Novartis drug Gilenya (fingolimod) has more than 20,000 patient-years of exposure and shows up to 71% reduction in annualized relapse rates in MS patients with highly active disease. October 17, 2011. Available at: http://www.novartis.com/newsroom/media-releases/en/2011/1555145.shtml.
  • 72 Seror R., Richez C., Sordet C. et al. Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey. Rheumatology (Oxford) 2013; 52 (05) 868-874.
  • 73 Kivisakk P., Healy B.C., Viglietta V. et al. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology 2009; 72 (22) 1922-1930.
  • 74 Bone H.G., Bolognese M.A., Yuen C.K. et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011; 96 (04) 972-980.
  • 75 Eisman J.A., Bone H.G., Hosking D.J. et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 2011; 26 (02) 242-251.
  • 76 Chen C.I., Bergsagel P.L., Paul H. et al. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia. J Clin Oncol 2011; 29 (09) 1175-1181.
  • 77 Farsaci B., Higgins J.P., Hodge J.W. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer 2012; 130 (08) 1948-1959.
  • 78 Boyce A., Chong W., Yao J. et al. Denosumab treatment for fibrous dysplasia. J Bone Miner Res 2012; 27 (07) 1462-1470.
  • 79 Reidenberg M.M. Drug discontinuation effects are part of the pharmacology of a drug. J Pharmacol Exp Ther 2011; 339 (02) 324-328.
  • 80 Václavík J., Táborský M. Antiplatelet therapy in the perioperative period. Eur J Intern Med 2011; 22 (01) 26-31.
  • 81 Rodríguez L.A., Cea-Soriano L., Martín-Merino E., Johansson S. Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. BMJ 2011; 343: d4094.
  • 82 García Rodríguez L.A., Cea Soriano L., Hill C., Johansson S. Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology 2011; 76 (08) 740-746.
  • 83 Gerstein N.S., Schulman P.M., Gerstein W.H., Petersen T.R., Tawil I. Should more patients continue aspirin therapy perioperatively?: clinical impact of aspirin withdrawal syndrome. Ann Surg 2012; 255 (05) 811-819.
  • 84 Amer M., Bead V.R., Bathon J., Blumenthal R.S., Edwards D.N. Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale. Cardiol Rev 2010; 18 (04) 204-212.
  • 85 Lordkipanidzé M., Harrison P. Beware of being caught on the rebound. J Thromb Haemost 2011; 9 (01) 21-23.
  • 86 Fosbøl E.L., Køber L., Torp-Pedersen C., Gislason G.H. Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals. Expert Opin Drug Saf 2010; 9 (06) 893-903.
  • 87 Corrao G., Conti V., Merlino L., Catapano A.L., Mancia G. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. Clin Ther 2010; 32 (02) 300-310.
  • 88 Pineda A., Cubeddu L.X. Statin rebound or withdrawal syndrome: does it exist?. Curr Atheroscler Rep 2011; 13 (01) 23-30.
  • 89 Dowlatshahi D., Demchuk A.M., Fang J., Kapral M.K., Sharma M., Smith E.E. Registry of the Canadian Stroke Network. Association of statins and statin discontinuation with poor outcome and survival after intracerebral hemorrhage. Stroke 2012; 43 (06) 1518-1523.
  • 90 De Vera M.A., Choi H., Abrahamowicz M., Kopec J., Lacaille D. Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken) 2012; 64 (06) 809-816.
  • 91 Flint A.C., Kamel H., Navi B.B. et al. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke 2012; 43 (01) 147-154.
  • 92 Hirst C., Calingaert B., Stanford R., Castellsague J. Use of long-acting beta-agonists and inhaled steroids in asthma: meta-analysis of observational studies. J Asthma 2010; 47 (04) 439-446.
  • 93 Bian B., Kelton C.M., Wigle P.R., Guo J.J. Evaluating safety of long-acting beta agonists (LABAs) in patients with asthma. Curr Drug Saf 2010; 5 (03) 245-250.
  • 94 Williams D. Long-acting β2 agonists for asthma: a clinical paradox. Consult Pharm 2010; 25 (11) 756-759.
  • 95 Ducharme F.M., Ni Chroinin M., Greenstone I., Lasserson T.J. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev 2010 (05); CD005535.
  • 96 Guo J.J., Tsai K., Kelton C.M., Bian B., Wigle P.R. Risk of serious asthma exacerbations associated with long-acting beta agonists among patients with asthma: a retrospective cohort study. Ann Allergy Asthma Immunol 2011; 106 (03) 214-222.
  • 97 Mysore S., Ruffin R.E. Long-acting β-agonists in asthma management: what is the current status?. Drugs 2011; 71 (16) 2091-2097.
  • 98 Cates C.J., Cates M.J. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2012; 4: CD006923.
  • 99 Valuck R.J., Orton H.D., Libby A.M. Antidepressant discontinuation and risk of suicide attempt: a retrospective, nested case-control study. J Clin Psychiatry 2009; 70 (08) 1069-1077.
  • 100 Howland R.H. Potential adverse effects of discontinuing psychotropic drugs: part 2: antidepressant drugs. J Psychosoc Nurs Ment Health Serv 2010; 48 (07) 9-12.
  • 101 Kraus J.E., Horrigan J.P., Carpenter D.J., Fong R., Barrett P.S., Davies J.T. Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy. J Affect Disord 2010; 120 (1–3): 40-47.
  • 102 Carpenter D.J., Fong R., Kraus J.E., Davies J.T., Moore C., Thase M.E. Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials. J Clin Psychiatry 2011; 72 (11) 1503-1514.
  • 103 Lerotić I., Baršić N., Stojsavljević S., Duvnjak M. Acid inhibition and the acid rebound effect. Dig Dis 2011; 29 (05) 482-486.
  • 104 Niv Y. Gradual cessation of proton pump inhibitor (PPI) treatment may prevent rebound acid secretion, measured by the alkaline tide method, in dyspepsia and reflux patients. Med Hypotheses 2011; 77 (03) 451-452.
  • 105 Juul-Hansen P., Rydning A. Clinical and pathophysiological consequences of on-demand treatment with PPI in endoscopy-negative reflux disease. Is rebound hypersecretion of acid a problem?. Scand J Gastroenterol 2011; 46 (04) 398-405.